Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma

Celeste Lebbe, MD, PhD
Published: Monday, Oct 23, 2017



Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.

In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.

The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
 
SELECTED
LANGUAGE


Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.

In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.

The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x